The Past and Future of Cancer Prevention and Control
Cancer prevention is central to the decline in cancer cases over the past decade, and researchers continue to work towards identifying factors that contribute to cancer development. In a recent paper, investigators from Rutgers Cancer Institute of New Jersey, Rutgers School of Public Health and Rutgers Robert Wood Johnson Medical School addressed the progress of behavioral and preventative medicine and the mission and vision of cancer prevention and control research in the future. Lead author Denalee O'Malley, PhD, along with senior author Shawna V. Hudson, PhD, share insight on the topic published as part of a special issue of Translational Behavioral Medicine: Practice, Policy, Research. Learn more
Key research findings to be presented at the 63rd Annual American Society of Hematology Meeting
Experts from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present several key hematology/ oncology research findings at the 63rd American Society of Hematology (ASH) Annual Meeting being held December 11-14. This includes more than 30 presentations examining leukemia, lymphoma, myeloma and other types of blood cancer, including research exploring the effects of SIRT1, an enzyme located primarily in the cell nucleus that contributes to cellular regulation on the transformation of T-cells, the impact of autoimmune diseases on patient outcomes and more. Learn more
Managing Cancer-Related Fatigue 
Fatigue, or the constant feeling of tiredness, is very common in people with cancer and can affect a patient physically, emotionally and mentally. Andrew Kass, RN, MSN, AGNP-C, AOCNP, Advanced practice nurse at Rutgers Cancer Institute of New Jersey, shares his insights about the signs and symptoms of cancer-related fatigue, as well as tips on how to better manage it. Learn more
Exploring How DNA Impacts Cancer Risk and Treatment
Investigators from Rutgers Cancer Institute of New Jersey and Dana-Farber Cancer Institute developed and evaluated a computational pipeline that utilizes information commonly provided in academic and commercial tumor sequencing assays to predict the origin of detected DNA alterations. Lead author and postdoctoral fellow Nahed Jalloul, PhD, along with senior author Hossein Khiabanian, PhD, Rutgers Cancer Institute resident research member and associate professor of pathology and laboratory medicine at Rutgers Robert Wood Johnson Medical School, share more about this work which was published in the November 17 online edition of JCO Precision Oncology. Learn more
As New Jersey’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, provides patients access to the most advanced treatment options including complex surgical procedures, sophisticated radiation therapy techniques, innovative clinical trials, immunotherapy, and precision medicine.